The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

Hoi Ki Karen TangChi Yeung FungGareth J MorganShaji K KumarLisa SiuHo Wan Alvin IpSze Fai YipKa Ngai Harry LauChi Kuen LauHarold LeeKwan Hung LeungBonnie KhoHoward WongCheong NgaiYu Yan HwangJoycelyn SimYok Lam KwongChor-Sang Chim

Published in: Therapeutic advances in hematology (2022)

+1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM.

Keyphrases

newly diagnosed
multiple myeloma
copy number
emergency department
human health
gene expression
risk assessment
dna methylation
climate change
adverse drug